Literature DB >> 31586838

Intermittent administration of low dose ketamine can shorten the course of electroconvulsive therapy for depression and reduce complications: A randomized controlled trial.

Jun Dong1, Su Min2, Haitang Qiu3, Qibing Chen1, Li Ren1.   

Abstract

This study aimed to investigate the efficacy and safety of intermittent low-dose ketamine on improving the efficacy of ECT. Patients diagnosed with Major Depressive Disorder (MDD) (n = 134) were randomized into 3 groups: routine ECT group (group E, n = 45); repeated ketamine-assisted ECT group (group RK, n = 43), and intermittent ketamine-assisted ECT group (group IK, n = 46). Patients in group RK were given ketamine at the dose of 0.3 mg/kg for each ECT treatment, patients in group IK were given ketamine once a week during ECT course. The depressive symptoms were assessed using the Hamilton Depression Rating Scale (HAM-D) at baseline, the end of ECT course, after 1 and 3 months, followed by an analysis of the psychiatric complications. Results indicated that ketamine-assisted ECT achieved a higher remission rate (P < 0.05), and no difference was observed between repeated and intermittent ketamine administrations. The total incidence rate of psychiatric complications in group RK (20.93%) was higher than that in group E (0%) and group IK (4.35%). In conclusion, intermittent administration of low dose ketamine in ECT significantly improved the effects of ECT and decreased psychiatric complications compared with repeated ketamine addition.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Complication; Curative effect; Depression; ECT; Ketamine

Mesh:

Substances:

Year:  2019        PMID: 31586838     DOI: 10.1016/j.psychres.2019.112573

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

Review 1.  Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis.

Authors:  Ashley A Conley; Amber E Q Norwood; Thomas C Hatvany; James D Griffith; Kathryn E Barber
Journal:  Psychopharmacology (Berl)       Date:  2021-03-31       Impact factor: 4.530

2.  Focal points of preanesthesia evaluations for electroconvulsive therapy in patients with depression: a retrospective analysis of clinical characteristics in nonremission.

Authors:  Lei Zou; Xiao Li; Qibin Chen; Feng Lv; Su Min
Journal:  BMC Anesthesiol       Date:  2022-05-26       Impact factor: 2.376

Review 3.  Pharmacological interventions to diminish cognitive side effects of electroconvulsive therapy: A systematic review and meta-analysis.

Authors:  Joey P A J Verdijk; Mike A van Kessel; Matthijs Oud; Charles H Kellner; Jeannette Hofmeijer; Esmée Verwijk; Jeroen A van Waarde
Journal:  Acta Psychiatr Scand       Date:  2022-02-08       Impact factor: 7.734

4.  Ketamine alleviating depressive-like behaviors is associated with regulation of nNOS-CAPON-Dexras1 complex in chronic unpredictable mild stress rats.

Authors:  Yiwei Shen; Feng Lv; Su Min; Xuechao Hao; Jian Yu
Journal:  Transl Neurosci       Date:  2022-09-21       Impact factor: 1.264

Review 5.  Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.

Authors:  Zach Walsh; Ozden Merve Mollaahmetoglu; Joseph Rootman; Shannon Golsof; Johanna Keeler; Beth Marsh; David J Nutt; Celia J A Morgan
Journal:  BJPsych Open       Date:  2021-12-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.